why choose us

Clinical Trials Search

Showing 7,450 of 132,656 result(s)
Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue

Status: Completed

Condition: HIV Infections

Interventions: colorectal biopsy for tissue acquisition

Date: 2023-10-20

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy (FOX)

Status: NOT_YET_RECRUITING

Condition: Duchenne Muscular Dystrophy

Interventions: EDG-5506 is administered orally once per day

Date: 2023-10-20

Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)

Status: Completed

Condition: Multiple Myeloma

Interventions: Teclistamab will be administered by subcutaneous (SC) injection per discretion of treating physician.
Participants will receive the recommended d

Date: 2023-10-20

CES for the Treatment of GAD in Young Adults

Status: NOT_YET_RECRUITING

Condition: Generalized Anxiety Disorder

Interventions: The stimulation paradigm in this trial consists of six weeks of daily, 60-minute at-home stimulation sessions.

Date: 2023-10-20

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Status: NOT_YET_RECRUITING

Condition: Metastatic Castration-resistant Prostate Cancer

Interventions: Testosterone Cypionate is an androgen and anabolic steroid medication which is used mainly in the treatment of low testosterone levels in men.

Date: 2023-10-20

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Status: Completed

Condition: Keratoconus

Interventions:

Drug: Ribostat riboflavin and sodium iodide ophthalmic solution

Device: UV-3000 ultraviolet A light source

Date: 2023-10-20

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Status: Completed

Condition: Vitiligo

Interventions: Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.

Date: 2023-10-20

Dose Ranging Study of SAR443765 Compared With Placebo-control in Adult Participants With Moderate to Severe Asthma

Status: Completed

Condition: Asthma

Interventions: Pharmaceutical form: solution for injection Route of administration: subcutaneous

Date: 2023-10-20

Study of Lenacapavir and Emtricitabine;Tenofovir Disoproxil Fumarate (F;TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN-102)

Status: Completed

Condition: Pre-Exposure Prophylaxis of HIV Infection

Interventions: Tablets administered orally without regard of food

Date: 2023-10-20